Paris (France), 05 January 2024 – Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for heart failure and obesity, today announced it has appointed Mark Pruzanski, MD, as Chairman of its Board of Directors. He replaces Thierry Laugel, Managing Partner at Kurma Partners, who remains a member of the Board.
Full PR is available here :https://corteriapharma.com/wp-content/uploads/2024/01/Corteria-PR-appointment-Chairman_Final.pdf